ClinicalTrials.gov
ClinicalTrials.gov Menu

PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02566603
Recruitment Status : Recruiting
First Posted : October 2, 2015
Last Update Posted : October 15, 2018
Sponsor:
Information provided by (Responsible Party):
Protalex, Inc.

Brief Summary:
Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP.

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenia Drug: PRTX-100 Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Study Start Date : November 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018


Arm Intervention/treatment
Experimental: PRTX-100
Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
Drug: PRTX-100
Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
Other Names:
  • SpA
  • Staphylococcal Protein A

Drug: PRTX-100
Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
Other Names:
  • SpA
  • Staphylococcal Protein A

Drug: PRTX-100
Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Other Names:
  • SpA
  • Staphylococcal Protein A

Drug: PRTX-100
Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Other Names:
  • SpA
  • Staphylococcal Protein A

Drug: PRTX-100
Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Other Names:
  • SpA
  • Staphylococcal Protein A




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by Toxicity Grading Criteria based on RCTC v 2.0 and CTCAE v 4.03 [ Time Frame: 337 Days ]
    Adverse events from AEs, SAEs, infusion reactions, clinical laboratory tests (hematology, blood chemistry and urinalysis), vital signs, physical findings and ECGs over the course of the study. AE severity will be graded according to Toxicity Grading Criteria derived from published standards.


Secondary Outcome Measures :
  1. Overall platelet response, change from baseline (Day 1) [ Time Frame: Days 1, 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    Defined as a platelet count ≥ 30,000/μL and at least a doubling of baseline platelet count in patients with a baseline platelet count <30,000/μL in the absence of any concomitant rescue therapy.

  2. Complete platelet response (number of patients) [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    The number of patients demonstrating a complete platelet response, defined as a platelet count ≥ 100,000/μL.

  3. Time to platelet response (number of days) [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    The mean number of days from first PRTX-100 dose (Day 1) until platelet response.

  4. Durability of platelet response (number of days) [ Time Frame: Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337 ]
    The number of days from first documented platelet response to first platelet count below platelet response criteria.

  5. Concomitant ITP medication use (number of subjects) [ Time Frame: 337 Days ]
    The number of subjects considered non-responders based on concomitant ITP medication use by cohort and overall. ITP medications include thrombopoietin receptor agonists (TPO-RAs), steroid-sparing adjunctive immunosuppressive treatment (e.g. cyclosporine, azathioprine, mycophenolate), and any ITP rescue medications (e.g. IVIG) received during the study Screening and Treatment Periods.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willing and able to provide written informed consent prior to initiation of any study-related procedures
  2. Male or female ≥ 18 years of age
  3. ITP that has persisted for ≥ 3 months. ITP must be diagnosed in accordance The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia (Neunert et al. 2011) or the International Consensus Report on The Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as locally applicable.
  4. Received ≥ 1 typical regimen for the treatment of ITP. Splenectomy is considered one regimen.
  5. A mean platelet count of < 30,000/μL with no individual platelet count > 55,000/μL. The mean platelet count must be determined based on 2 platelet counts including one obtained within ≤ 7 days of first PRTX-100 dose and the other within ≤ 30 days of the first dose of PRTX-100.
  6. If on corticosteroids, a dose of < 1 mg/kg prednisone per day or equivalent that has been stable for ≥ 21 days prior to the first dose of PRTX-100. High-dose pulse steroid therapy is NOT allowed within 14 days prior to the first dose of PRTX-100.
  7. If on steroid-sparing adjunctive immunosuppression with cyclosporine, azathioprine, mycophenolate, or 6-mercaptopurine, the dose must have been stable for ≥ 30 days prior to the first dose of PRTX-100 and must be expected to remain stable through study Day 29, unless dose reduction is required due to toxicities. Treatment with other cytotoxic agents (e.g. cyclophosphamide, vincristine) are not allowed within three months prior to the first dose of PRTX- 100.
  8. Any prior treatment with rituximab or any other anti-CD20 agent must have been > 6 months prior to the first dose of PRTX-100
  9. If female, must not be pregnant (as indicated by screening negative pregnancy test), must not be nursing and must be one of the following:

    • Surgically sterile (bilateral tubal ligation, hysterectomy)
    • Postmenopausal with last natural menses > 24 months prior
    • Premenopausal and using an acceptable form of birth control. Acceptable forms of birth control include: hormonal contraceptives (implantable, oral, patch) used for ≥ 2 months prior to screening or double barrier methods (any combination of two of the following: intrauterine device [IUD], male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). All premenopausal females must have a negative urine or serum pregnancy test at screening and on Day 1 prior to first PRTX-100 treatment.

Exclusion Criteria:

  1. Splenectomy ≤ 90 days prior to the first dose of PRTX-100
  2. Exposure to TPO-RA within 2 weeks before inclusion
  3. Previous treatment with rituximab within <6 months prior to the first dose of PRTX-100
  4. Bleeding score ≥ 8 (Khellaf M et al. Haematologica 2005)
  5. Unstable coronary artery disease or other medical condition (such as type 1 diabetes) that, in the investigator's opinion, might increase the risk to the patient
  6. Evidence of active infection requiring antibiotic therapy ≤ 14 days prior to the first dose of PRTX-100
  7. Myelodysplastic syndrome. If clinically significant anemia or pancytopenia exists, documentation of a bone marrow aspirate within 24 months prior to the first dose of PRTX- 100 showing no evidence of myelodysplasia is required.
  8. Medical history systemic lupus erythematosus or any cause of secondary ITP
  9. History of any treatment for cancer within the past two years other than basal cell or squamous cell carcinoma of the skin that has been treated with curative intent
  10. Seropositive for human immunodeficiency virus (HIV)
  11. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B or C (positive for hepatitis B surface antigen or positive anti-hepatitis C antibody test)
  12. History suggestive of substance abuse
  13. Clinically significant abnormalities in screening laboratory tests, including:

    • Absolute neutrophil count < 1.0 x109/L
    • Hemoglobin < 10 g/dL
    • Absolute lymphocyte count < 0.8 x109/L
    • Alanine transaminase (ALT) or aspartate transaminase (AST) > 2 x upper limit of normal (ULN)
    • Lactate dehydrogenase > 3 x ULN
    • Total bilirubin level >1.5 x ULN
    • Serum creatinine level > 0.14 mmol/L (1.6 mg/dL) in males or 0.12 mmol/L (1.4 mg/dL) in females
  14. Treatment with IVIG ≤ 14 days prior to the first dose of PRTX-100
  15. Treatment with an anti-Rh D antigen agent (e.g. WinRho®) ≤ 14 days prior to the first dose of PRTX-100
  16. Use of any investigational drug ≤ 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first dose of PRTX-100

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02566603


Contacts
Contact: William E Gannon, MD 508-487-1060 WGannon@capcitytek.com

Locations
France
Haut-Levêque Hospital Active, not recruiting
Pessac, Bordeaux, France, 33600
CH Lyon Sud Active, not recruiting
Pierre-Bénite, Lyon, France, 69495
Côte de Nacre Hospital Active, not recruiting
Caen, France, 14033
Mondor Hospital Active, not recruiting
Créteil, France, 94010
University Hospital Active, not recruiting
Dijon, France, 21000
Claude Huriez Hospital Active, not recruiting
Lille, France, 59037
CH La Timone Active, not recruiting
Marseille, France, 13385
CHU Active, not recruiting
Nantes, France, 44093
Canceropole Active, not recruiting
Toulouse, France, 31059
United Kingdom
Hammersmith Hospital Recruiting
London, OHS, United Kingdom, W12
Contact: Deena Paul    02033134306    Deena.Paul@imperial.nhs.uk   
Principal Investigator: Nichola Cooper, MD         
UCLH Recruiting
London, UK, United Kingdom, NW1 2BU
Contact: Ingrid Obu    0207 6796428    ingrid.obu@uclh.nhs.uk   
Principal Investigator: Marie Scully, MD         
Guy's and St. Thomas Hospital Recruiting
London, UK, United Kingdom, SE 19RT
Contact: Thompson Olaoni       Olaoni.Thompson@gstt.nhs.uk   
Principal Investigator: Susan Robinson, MD         
St. Georges' Hospital Recruiting
London, UK, United Kingdom, SW17 0QT
Contact: Pearl Quartey       Pearl.Quarteu@stgeorges.nhs.uk   
Principal Investigator: Steve Austin, MD         
Derriford Hospital Recruiting
Plymouth, UK, United Kingdom, PL6 8DH
Contact: Nicola Crosbie       nicola.crosbie@nhs.net   
Principal Investigator: Tim Nokes, MD         
University Hospital Southampton Recruiting
Southampton, UK, United Kingdom, SO16 6YD
Contact: Caroline Grabau       Caroline.Grabau@uhs.nhs.uk   
Principal Investigator: Rashid Kazmi, MD         
Royal London Hospital Recruiting
London, United Kingdom
Contact: Louise Taylor    02032460261    Louise.Taylor@bartshealth.nhs.uk   
Principal Investigator: Adrian C Newland, Prof.         
Sponsors and Collaborators
Protalex, Inc.
Investigators
Study Director: William E Gannon, MD Protalex, Inc.

Responsible Party: Protalex, Inc.
ClinicalTrials.gov Identifier: NCT02566603     History of Changes
Other Study ID Numbers: PRTX-100-203
2014-005626-35 ( EudraCT Number )
First Posted: October 2, 2015    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018

Keywords provided by Protalex, Inc.:
ITP
Thrombocytopenia

Additional relevant MeSH terms:
Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Purpura
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Signs and Symptoms